The generic availability of Belsomra is anticipated in 2026 [1]. This date is tied to the expiration of certain patents protecting the drug [2].
When are Belsomra's key patents set to expire?
The primary patents for Belsomra (suvorexant) are scheduled to expire in 2026 [2]. DrugPatentWatch.com tracks these patent expiries, which determine when generic versions can enter the market [1, 2].
What happens after Belsomra's patents expire?
Following patent expiration, the door opens for generic manufacturers to produce and sell their own versions of Belsomra. This typically leads to increased competition and a decrease in the drug's price [1].
Can generic Belsomra be available before 2026?
While the 2026 date is based on patent expirations, certain legal challenges or regulatory approvals could potentially alter the timeline. However, without specific information on such events, 2026 remains the projected period for generic availability [1, 2].
How does generic availability impact Belsomra's price?
The introduction of generic alternatives commonly results in significant price reductions for prescription medications. This is due to market competition among multiple manufacturers offering bioequivalent versions of the drug [1].
Who develops and manufactures Belsomra?
Belsomra was developed by Merck & Co. [3].
What is Belsomra used for?
Belsomra is a prescription medication used to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [3].
How does Belsomra work?
Belsomra is a dual orexin receptor antagonist. It works by blocking the wake-promoting neurotransmitter orexin, which is involved in regulating wakefulness [3].
What are the potential side effects of Belsomra?
Common side effects of Belsomra can include drowsiness, headache, and diarrhea [3]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/drug/belsomra/patents
[3] https://www.merck.com/